Levin V A, Hoffman W F, Heilbron D C, Norman D
J Neurosurg. 1980 May;52(5):642-7. doi: 10.3171/jns.1980.52.5.0642.
Case histories of 61 patients receiving multimodality therapy for primary malignant brain tumors were reviewed for factors visible on the computerized tomography (CT) scan that correlated with the interval of time from diagnosis and pretherapy evaluation to the time of documented tumor progression. The initial pretreatment CT scan of each patient was reviewed. Midline shift, peritumor low density (edema), the greatest diameter of tumor enhancement, and the greatest diameter of the intratumor low-density area were measured prior to radiation therapy and chemotherapy. Using a Weibull survival probability model, time to tumor progression was most satisfactorily fitted using two covariates, the volume of enhancing tumor (for instance, contrast-enhancing tumor less intratumor low density), and the presence of a peritumor low-density area. Patients who exhibited a small amount of contrast-enhancing tumor with peritumor low density tended to have a longer time to progression than patients with large contrast-enhancing tumor volume and no peritumor low density. Midline shift was not as important a variable as the extent of tumor contrast enhancement or peritumor low density.
回顾了61例接受原发性恶性脑肿瘤多模态治疗患者的病历，以寻找计算机断层扫描（CT）上可见的与从诊断和治疗前评估到记录的肿瘤进展时间间隔相关的因素。对每位患者的初始治疗前CT扫描进行了回顾。在放疗和化疗前测量中线移位、肿瘤周围低密度（水肿）、肿瘤强化的最大直径和肿瘤内低密度区域的最大直径。使用威布尔生存概率模型，肿瘤进展时间最适合用两个协变量来拟合，即强化肿瘤的体积（例如，对比增强肿瘤减去肿瘤内低密度区域）和肿瘤周围低密度区域的存在。与具有大的对比增强肿瘤体积且无肿瘤周围低密度的患者相比，表现为少量对比增强肿瘤且伴有肿瘤周围低密度的患者往往有更长的进展时间。中线移位不像肿瘤对比增强程度或肿瘤周围低密度那样是一个重要变量。
